Ruggieri S, Stocchi F, Carta A, Bravi D, Bragoni M, Giorgi L, Agnoli A
Department of Neurological Sciences, La Sapienza University, Rome, Italy.
Mov Disord. 1988;3(4):313-9. doi: 10.1002/mds.870030405.
L-Dopa is still the most effective drug for the treatment of Parkinson's Disease, but after 5 years or more of therapy fluctuations in motor performance and abnormal involuntary movements commonly appear. Continuous intravenous infusions of L-Dopa abolish or strikingly reduce such fluctuations. Unfortunately, this is not suitable for daily treatment because of the low solubility of L-Dopa. Lisuride is a potent dopamine agonist and is very soluble in water. In this study the clinical effects of L-Dopa and lisuride continuous intravenous infusions were compared in a group of 20 fluctuating parkinsonian patients. L-Dopa controlled fluctuations in almost all the subjects, whereas only seven patients were continuously mobile while taking lisuride. Another seven patients showed a fluctuating response and the remaining six did not satisfactorily respond to lisuride. Dyskinesias were present in all patients during "on" phases, with both levodopa and lisuride treatment.
左旋多巴仍然是治疗帕金森病最有效的药物，但经过5年或更长时间的治疗后，运动功能波动和异常不自主运动通常会出现。持续静脉输注左旋多巴可消除或显著减少此类波动。不幸的是，由于左旋多巴的低溶解度，这不适合日常治疗。利苏瑞肽是一种强效多巴胺激动剂，在水中溶解度很高。在本研究中，对一组20例运动波动型帕金森病患者比较了左旋多巴和利苏瑞肽持续静脉输注的临床效果。左旋多巴几乎控制了所有受试者的波动，而服用利苏瑞肽时只有7例患者能持续活动。另外7例患者反应波动，其余6例对利苏瑞肽反应不佳。在左旋多巴和利苏瑞肽治疗的“开”期，所有患者均出现运动障碍。
